Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
MIRA Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
MIRA
Nasdaq
2834
mirapharmaceuticals.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for MIRA Pharmaceuticals, Inc.
Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation
- Jan 5th, 2025 1:16 pm
Memecoin Degens Raise Millions for Rare Cancer Research After a Father’s Plea
- Dec 27th, 2024 7:56 am
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development
- Dec 19th, 2024 2:00 pm
EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment
- Dec 19th, 2024 1:25 pm
MIRA Makes Major Strides
- Dec 19th, 2024 10:05 am
MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End
- Dec 10th, 2024 1:30 pm
EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain
- Dec 10th, 2024 1:15 pm
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
- Nov 20th, 2024 12:44 pm
MIRA Continues Solid Financial Management
- Nov 13th, 2024 11:00 am
MIRA Pharmaceuticals Shares Surge 40% After Ketamir-2 Excels in Pain Management Trials
- Oct 29th, 2024 2:57 pm
MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain
- Oct 28th, 2024 5:41 pm
MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
- Oct 28th, 2024 11:30 am
Weekly Roundup on the Cannabis Sector & Psychedelic Sector 10-28-2024
- Oct 27th, 2024 9:34 pm
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
- Oct 21st, 2024 11:30 am
MIRA Continues to Post Outstanding Test Results
- Oct 21st, 2024 10:20 am
MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
- Sep 27th, 2024 11:30 am
MIRA Makes Impressive Progress
- Sep 18th, 2024 3:18 pm
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025
- Sep 18th, 2024 11:00 am
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
- Sep 11th, 2024 11:30 am
MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study
- Aug 26th, 2024 12:00 pm
Scroll